Compare · BIIB vs WWB
BIIB vs WWB
Side-by-side comparison of Biogen Inc. (BIIB) and Windward Bio Group AG (WWB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIIB and WWB operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BIIB is the larger of the two at $37.16B, about 27.5x WWB ($1.35B).
- Both names hit the wire about 14 times in the past 4 weeks.
- BIIB has more recent analyst coverage (25 ratings vs 0 for WWB).
- Company
- Biogen Inc.
- Windward Bio Group AG
- Price
- -
- -
- Market cap
- $37.16B
- $1.35B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2026
- News (4w)
- 14
- 14
- Recent ratings
- 25
- 0
Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Windward Bio Group AG
Windward Bio Group is a clinical-stage biotechnology company developing ultra-long-acting antibody medicines for patients with serious respiratory and dermatologic diseases, including asthma, chronic obstructive pulmonary disease, or COPD, and atopic dermatitis. Our product candidates, WIN378 and WIN027, target clinically validated disease pathways and are engineered to remain in the body for extended periods of time, enabling less frequent dosing than currently available treatments. This design feature is combined with additional properties including enhanced target affinity, dual target binding or effector function silencing. We believe our product candidates have the potential to deliver better clinical outcomes while offering the convenience of less frequent dosing than currently available treatments.
Latest BIIB
- New Three-Year Real-World LEQEMBI® Data Presented at CTAD 2026
- Biogen’s Diranersen Demonstrates Increasing Clinical Benefit at Two Years in Early Alzheimer’s Disease
- New Five-Year Lecanemab Data from Clarity AD Study Long-Term Extension Presented at CTAD 2026
- FDA Approval for ZURZUVAE issued to BIOGEN
- LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Now Available in Japan for Patients with Early Alzheimer’s Disease
- SEC Form SCHEDULE 13G filed by Biogen Inc.
- ACR 2026: Dapirolizumab Pegol Associated with Greater Treatment Response Rates Versus Placebo in SLE Using Novel Treatment Response Measure
- Stoke Therapeutics to Present at Upcoming Investor Conferences in November
- Head of Research Grogan Jane converted options into 695 shares and covered exercise/tax liability with 345 shares, increasing direct ownership by 9% to 4,408 units (SEC Form 4)
- Stoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Updates
Latest WWB
- Director David P Bonita bought $20,000,007 worth of shares (1,176,471 units at $17.00), converted options into 5,172,944 shares, exercised 216,668 shares at a strike of $0.02 and covered exercise/tax liability with 232 shares (SEC Form 4)
- Director Orbimed Advisors Llc bought $20,000,007 worth of shares (1,176,471 units at $17.00), converted options into 5,172,944 shares, exercised 216,668 shares at a strike of $0.02 and covered exercise/tax liability with 232 shares (SEC Form 4)
- Director Otello Stampacchia bought $29,750,000 worth of shares (1,750,000 units at $17.00) and converted options into 3,588,520 shares (SEC Form 4)
- Windward Bio to Participate at the Jefferies London Global Healthcare Conference
- Director Mufti Iqbal Rasool was granted 22,675 share options (SEC Form 4)
- Chief Operating Officer Harris Kevin Andrew was granted 33,206 shares, increasing direct ownership by 4% to 960,966 units (SEC Form 4)
- Chief Executive Officer Santarelli Luca was granted 815,755 employee share options (SEC Form 4)
- Chief Financial Officer D'Augusta Claudia was granted 180,160 employee share options (SEC Form 4)
- Director Bonita David P was granted 22,675 stock options (SEC Form 4)
- Director Stampacchia Otello was granted 22,675 share options (SEC Form 4)